← Back to Search

Bias Mitigation Training for End-of-Life Care (BRiDgE Trial)

N/A

Recruiting

Led By Elizabeth Chuang, MD

Research Sponsored by Montefiore Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up during the intervention

Awards & highlights

BRiDgE Trial Summary

This trial will help determine whether a training intervention can reduce the effects of clinician implicit racial bias on communication with family members of patients near the end of life.

Who is the study for?

This trial is for physicians specializing in oncology, critical care, hospitalist medicine, emergency medicine or geriatrics who frequently care for seriously ill patients. It's not open to those trained in Hospice and Palliative Medicine or doctors who spend less than 10% of their time with critically ill hospitalized patients.Check my eligibility

What is being tested?

The study tests a training program designed to improve how doctors communicate with families of critically ill patients by reducing racial biases. Doctors will be randomly assigned to either bias mitigation plus communication training or just communication training and then evaluated on their interactions.See study design

What are the potential side effects?

Since this trial involves educational interventions rather than medical treatments, traditional physical side effects are not applicable. However, participants may experience changes in awareness and attitudes towards their own implicit biases.

BRiDgE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ during the intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~during the intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and during the intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

verbal dominance

Secondary outcome measures

Nonverbal communication

Verbal communication

encounter duration

BRiDgE Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Communication and Bias Mitigation TrainingExperimental Treatment1 Intervention

This is a communication training session based on a culturally-based program developed with rural, southern Black patients and families and modified for an urban, northern population. A strategy of bias mitigation successfully used with medical students will be adapted for practicing clinicians using results of phase 1. This strategy is based on transformational learning theory and incorporates critical reflection, guided dialogue, perspective taking exercises, role plays and strategy development. If specific communication behaviors are found related to bias and stereotyping in phase 1, these will be discussed and targeted using these techniques. Otherwise, these techniques will be used to address racial bias generally. The intervention will be incorporated within the communication training session.

Group II: Communication Training OnlyActive Control1 Intervention

This is a communication training session based on standard palliative care techniques to listen empathically, share prognostic information and treatment options, elicit patient and family goals and values related to their treatment, and facilitate shared decision-making regarding end-of-life treatment.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Montefiore Medical CenterLead Sponsor

441 Previous Clinical Trials

582,146 Total Patients Enrolled

Elizabeth Chuang, MDPrincipal InvestigatorMontefiore Medical Center/Albert Einstein College of Medicine

Media Library

Communication and Bias Mitigation Training Clinical Trial Eligibility Overview. Trial Name: NCT05165888 — N/A

Disease Research Study Groups: Communication and Bias Mitigation Training, Communication Training Only

Disease Clinical Trial 2023: Communication and Bias Mitigation Training Highlights & Side Effects. Trial Name: NCT05165888 — N/A

Communication and Bias Mitigation Training 2023 Treatment Timeline for Medical Study. Trial Name: NCT05165888 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies left to participate in this trial?

"Our assessment of the clinicaltrials.gov data indicates that this trial is no longer accepting participants; it was originally posted on February 3rd 2022 and last updated November 23rd 2022. However, there are presently 257 other medical studies which are actively recruiting patients."

Answered by AI

Recent research and studies

The GerontologistJournal

Current Research Findings on End-of-life Decision Making Among Racially or Ethnically Diverse Groups

Kwak, J., and W. E. Haley. 2005. “Current Research Findings on End-of-life Decision Making Among Racially or Ethnically Diverse Groups”. The Gerontologist. Oxford University Press (OUP). doi:10.1093/geront/45.5.634.

Journal of Pain and Symptom ManagementJournal

Multiple Stakeholders' Perspectives Regarding Barriers to Hospice Enrollment in Diverse Patient Populations: A Qualitative Study

Cicolello, Katherine, and Gowri Anandarajah. 2019. “Multiple Stakeholders' Perspectives Regarding Barriers to Hospice Enrollment in Diverse Patient Populations: A Qualitative Study”. Journal of Pain and Symptom Management. Elsevier BV. doi:10.1016/j.jpainsymman.2019.02.012.

Critical Care MedicineJournal

A Randomized Trial of the Effect of Patient Race on Physiciansʼ Intensive Care Unit and Life-sustaining Treatment Decisions for an Acutely Unstable Elder with End-stage Cancer*

Barnato, Amber E., Deepika Mohan, Julie Downs, Cindy L. Bryce, Derek C. Angus, and Robert M. Arnold. 2011. “A Randomized Trial of the Effect of Patient Race on Physiciansʼ Intensive Care Unit and Life-sustaining Treatment Decisions for an Acutely Unstable Elder with End-stage Cancer*”. Critical Care Medicine. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/ccm.0b013e3182186e98.

Social Science & MedicineJournal